Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.88) by 19.32 percent. This is a 13.41 percent increase over losses of $(0.82) per share from the same period last year. The company reported quarterly sales of $34.365 million which beat the analyst consensus estimate of $8.614 million by 298.95 percent. This is a 55.50 percent increase over sales of $22.100 million the same period last year.